Search

Your search keyword '"Vink, Geraldine R."' showing total 329 results
Start Over Author "Vink, Geraldine R."
329 results on '"Vink, Geraldine R."'

6. Results from the UNITED study: a multicenter study validating the prognostic effect of the tumor–stroma ratio in colon cancer

Author

Petrushevska, Gordana, Bogdanovska, Magdalena, Zdravkoski, Panche, Antovic, Svetozar, Dzambaz, Darko, Karagjozov, Panche, de Cuba, Erienne M.V., Beverdam, Frédérique, Jansen, Jan, Vermaas, Maarten, Gašljević, Gorana, Kjær-Frifeldt, Sanne, Lindebjerg, Jan, Strous, Maud, Vogelaar, Jeroen F., Bulkmans, Nicole W.J., van Baarlen, Joop, Mekenkamp, Leonie, Hoekstra, Ronald, Sie, Mark, Cuatrecasas, Miriam, Simonetti, Sara, Rodrigo, María Teresa, Sanz, Iván Archilla, Guerrero Pineda, Jose, Leeuwis-Fedorovich, Natalja E., Talsma, Koen A., Souza da Silva, Ricella M., Lacle, Miangela M., Koopman, Miriam, Dekker, Jan Willem T., van Tilburg, Arjan, Nuciforo, Paolo, Villalobos Alberú, Xenia, Landolfi, Stefania, Zucchiatti, Adriana, Witteveen, Emma, Bordbar, Arad, Hendriks, Mathijs P., Arensman, René, Natu, Shonali, Maka, Noori, Mesker, Wilma E., Tollenaar, Rob A.E.M., Polack, Meaghan, Smit, Marloes A., van Pelt, Gabi W., Putter, Hein, Meershoek-Kleinenbarg, Elma, Roodvoets, Annet G.H., Crobach, Augustinus S.L.P., Gelderblom, Hans, Fontes e Sousa, Mário, Borralho Nunes, Paula, Cruz, João, Raimundo, Ana, Silva, Nelson, Brito, Maria J., Terpstra, Valeska, Zakhartseva, L.M., Al Dieri, Raed, Fléjou, Jean-François, Feakins, Roger, Dequeker, Els, Vink, Geraldine R., van Krieken, J.Han J.M., Polack, M., Smit, M.A., van Pelt, G.W., Roodvoets, A.G.H., Meershoek-Klein Kranenbarg, E., Putter, H., Gelderblom, H., Crobach, A.S.L.P., Terpstra, V., Petrushevska, G., Gašljević, G., Kjær-Frifeldt, S., de Cuba, E.M.V., Bulkmans, N.W.J., Vink, G.R., Al Dieri, R., Tollenaar, R.A.E.M., van Krieken, J.H.J.M., and Mesker, W.E.

Published
2024
Full Text
View/download PDF

7. The Assessment of Burden of ColoRectal Cancer (ABCRC)-tool; a validity and reliability study

Author

Thomassen, Britt J.M., Kimman, Merel L., Somers, Anne M.J., Ponds, Rudolf W.H.M., Dekker, Jan Willem T., van Leiden, Barbara L., Vink, Geraldine R., de Groot, Jan Willem B., Melenhorst, Jarno, Reynders, Kim M.M.W., Gielen, Christel M.J., Weerts, Tom H.A., Lutke Holzik, Martijn F., van Kuijk, Sander M.J., Breukink, Stéphanie O., and Gidding-Slok, Annerika H.M.

Published
2024
Full Text
View/download PDF

10. Towards patient-led follow-up after curative surgical resection of stage I, II and III colorectal cancer (DISTANCE-trial): a study protocol for a stepped-wedge cluster-randomised trial

Author

Swartjes, Hidde, Qaderi, Seyed M., Teerenstra, Steven, Custers, Jose A. E., Elferink, Marloes A. G., van Wely, Bob J., Burger, Jacobus W. A., van Grevenstein, Wilhelmina M. U., van Duijvendijk, Peter, Verdaasdonk, Emiel G. G., de Roos, Marnix A. J., Coupé, Veerle M. H., Vink, Geraldine R., Verhoef, Cornelis, and de Wilt, Johannes H. W.

Published
2023
Full Text
View/download PDF

14. Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS)

Author

Beerepoot, Laurens V., Creemers, Geert-Jan, van Cruijsen, Hester, de Groot, Jan Willem B., van Halteren, Henk K., Helgason, Helgi H., Hendriks, Mathijs P., Hoekstra, Ronald, van Huis-Tanja, Lieke H., Kapiteijn, Ellen, Los, Maartje, van Meerten, Esther, Peters, Natascha A.J.B., Pruijt, Johannes F.M., van Ufford-Mannesse, Patricia Quarles, Sie, Mark P.S., Sommeijer, Dirkje W., Spierings, Leontine E.A.M.M., Terheggen, Frederiek, Tjin-A-Ton, Manuel L.R., Valkenburg-van Iersel, Liselot B.J., van Voorthuizen, Theo, de Vos-Geelen, Judith, Vulink, Annelie J.E., J van de Wouw, Agnès, Hamers, Patricia A.H., Vink, Geraldine R., Elferink, Marloes A.G., Stellato, Rebecca K., Dijksterhuis, Willemieke P.M., Punt, Cornelis J.A., Koopman, Miriam, and May, Anne M.

Published
2022
Full Text
View/download PDF

15. Quality of life and functional outcome of rectal cancer patients: A prospective cohort study.

Author

Pennings, Alexander J., Vink, Geraldine R., van Kuijk, Sander, Melenhorst, Jarno, Beets, Geerard L., May, Anne M., and Breukink, Stephanie O.

Subjects
*COLORECTAL cancer, *MINIMALLY invasive procedures, *CANCER prognosis, *FUNCTIONAL status, *MEDICAL screening
Abstract

Aim: In the last decade, the Netherlands has implemented various diagnostic and treatment strategies to enhance rectal cancer outcomes. This study, using data from the Prospective Dutch ColoRectal Cancer (PLCRC) cohort, investigates whether these multidisciplinary advancements have translated into improved health‐related quality of life (HRQoL) and functional outcomes for the general Dutch rectal cancer population. Methods: Patients with Stage I–III rectal cancer enrolled in the PLCRC cohort were included. HRQoL and functional outcomes were assessed 1 and 2 years after diagnosis using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ‐C30), EORTC QLQ Colorectal Cancer 29 and the Low Anterior Resection Syndrome score. HRQoL and functional outcomes were compared based on year of diagnosis (2014–2019). Results: A total of 1294 patients were included. Two years after diagnosis, patients diagnosed in 2019 (n = 392) had a clinically relevant higher score on physical (8.2, 95% CI 4.1–12.3), role (13.5, 95% CI 7.3–19.7) and social functioning (5.8, 95% CI 0.3–11.2) compared to those diagnosed in 2014 (n = 65). Additionally, patients diagnosed in 2019 experienced less fatigue 2 years after diagnosis compared to those diagnosed in 2014 (−8.6, 95% CI −14.1 to −3.0). The Low Anterior Resection Syndrome score showed no differences. Conclusion: The findings of this study suggest that over the past decade rectal cancer patients in the Netherlands have witnessed improvements in HRQoL across various domains. Most probably, the improvement is due to a combination of implementation of population screening, a more restrictive neoadjuvant radiotherapy policy and advances in minimally invasive surgery and organ preserving treatment options. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. A scenario‐drafting study to explore potential future implementation pathways of circulating tumor DNA testing in oncology.

Author

Kramer, Astrid, Rubio‐Alarcón, Carmen, van den Broek, Daan, Vessies, Daan C. L., van't Erve, Iris, Meijer, Gerrit A., Vink, Geraldine R., Schuuring, Ed, Fijneman, Remond J. A., Coupé, Veerle M. H., and Retèl, Valesca P.

Abstract

Circulating tumor DNA (ctDNA) detection has multiple promising applications in oncology, but the road toward implementation in clinical practice is unclear. We aimed to support the implementation process by exploring potential future pathways of ctDNA testing. To do so, we studied four ctDNA‐testing applications in two cancer types and elicited opinions from 30 ctDNA experts in the Netherlands. Our results showed that the current available evidence differed per application and cancer type. Tumor profiling and monitoring treatment response were found most likely to be implemented in non‐small cell lung cancer (NSCLC) within 5 years. For colorectal cancer, applications of ctDNA testing were found to be at an early stage in the implementation process. Demonstrating clinical utility was found a key aspect for successful implementation, but there was no consensus regarding the evidence requirements. The next step toward implementation is to define how clinical utility of biomarkers should be evaluated. Finally, these data indicate that specific challenges for each clinical application and tumor type should be appropriately addressed in a deliberative process involving all stakeholders to ensure implementation of ctDNA testing and timely access for patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study

Author

van Bergeijk, Jeroen, Wiersma, Tjerk, van Grevenstein, Wilhelmina, Frasa, Marieke, van Gestel, Linda, Meijer, Gerrit, Breekveldt, Emilie C H, Lansdorp-Vogelaar, Iris, Toes-Zoutendijk, Esther, Spaander, Manon C W, van Vuuren, Anneke J, van Kemenade, Folkert J, Ramakers, Christian R B, Dekker, Evelien, Nagtegaal, Iris D, Krul, Myrtle F, Kok, Niels F M, Kuhlmann, Koert F D, Vink, Geraldine R, van Leerdam, Monique E, and Elferink, Marloes A G

Published
2022
Full Text
View/download PDF

18. Frailty and health related quality of life three months after non-metastatic colorectal cancer diagnosis in older patients: A multi-centre prospective observational study

Author

van der Vlies, Ellen, Vernooij, Lisette M., Hamaker, Marije E., van der Velden, Ankie M.T., Smits, Marianne, Intven, Martijn P.W., van Dodewaard, Joyce M., Takkenberg, Marijn, Vink, Geraldine R., Smits, Anke B., Bos, Willem Jan W., van Dongen, Eric P.A., Los, Maartje, and Noordzij, Peter G.

Published
2022
Full Text
View/download PDF

19. A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues

Author

de Back, Tim R, primary, Wu, Tan, additional, Schafrat, Pascale JM, additional, ten Hoorn, Sanne, additional, Tan, Miaomiao, additional, He, Lingli, additional, van Hooff, Sander R, additional, Koster, Jan, additional, Nijman, Lisanne E, additional, Vink, Geraldine R, additional, Beumer, Inès J, additional, Elbers, Clara C, additional, Lenos, Kristiaan J, additional, Sommeijer, Dirkje W, additional, Wang, Xin, additional, and Vermeulen, Louis, additional

Published
2024
Full Text
View/download PDF

20. Results from the UNITED study: a multicenter study validating the prognostic effect of the tumor–stroma ratio in colon cancer

Author

Polack, M., primary, Smit, M.A., additional, van Pelt, G.W., additional, Roodvoets, A.G.H., additional, Meershoek-Klein Kranenbarg, E., additional, Putter, H., additional, Gelderblom, H., additional, Crobach, A.S.L.P., additional, Terpstra, V., additional, Petrushevska, G., additional, Gašljević, G., additional, Kjær-Frifeldt, S., additional, de Cuba, E.M.V., additional, Bulkmans, N.W.J., additional, Vink, G.R., additional, Al Dieri, R., additional, Tollenaar, R.A.E.M., additional, van Krieken, J.H.J.M., additional, Mesker, W.E., additional, Petrushevska, Gordana, additional, Bogdanovska, Magdalena, additional, Zdravkoski, Panche, additional, Antovic, Svetozar, additional, Dzambaz, Darko, additional, Karagjozov, Panche, additional, de Cuba, Erienne M.V., additional, Beverdam, Frédérique, additional, Jansen, Jan, additional, Vermaas, Maarten, additional, Gašljević, Gorana, additional, Kjær-Frifeldt, Sanne, additional, Lindebjerg, Jan, additional, Strous, Maud, additional, Vogelaar, Jeroen F., additional, Bulkmans, Nicole W.J., additional, van Baarlen, Joop, additional, Mekenkamp, Leonie, additional, Hoekstra, Ronald, additional, Sie, Mark, additional, Cuatrecasas, Miriam, additional, Simonetti, Sara, additional, Rodrigo, María Teresa, additional, Sanz, Iván Archilla, additional, Guerrero Pineda, Jose, additional, Leeuwis-Fedorovich, Natalja E., additional, Talsma, Koen A., additional, Souza da Silva, Ricella M., additional, Lacle, Miangela M., additional, Koopman, Miriam, additional, Dekker, Jan Willem T., additional, van Tilburg, Arjan, additional, Nuciforo, Paolo, additional, Villalobos Alberú, Xenia, additional, Landolfi, Stefania, additional, Zucchiatti, Adriana, additional, Witteveen, Emma, additional, Bordbar, Arad, additional, Hendriks, Mathijs P., additional, Arensman, René, additional, Natu, Shonali, additional, Maka, Noori, additional, Mesker, Wilma E., additional, Tollenaar, Rob A.E.M., additional, Polack, Meaghan, additional, Smit, Marloes A., additional, van Pelt, Gabi W., additional, Putter, Hein, additional, Meershoek-Kleinenbarg, Elma, additional, Roodvoets, Annet G.H., additional, Crobach, Augustinus S.L.P., additional, Gelderblom, Hans, additional, Fontes e Sousa, Mário, additional, Borralho Nunes, Paula, additional, Cruz, João, additional, Raimundo, Ana, additional, Silva, Nelson, additional, Brito, Maria J., additional, Terpstra, Valeska, additional, Zakhartseva, L.M., additional, Al Dieri, Raed, additional, Fléjou, Jean-François, additional, Feakins, Roger, additional, Dequeker, Els, additional, Vink, Geraldine R., additional, and van Krieken, J.Han J.M., additional

Published
2024
Full Text
View/download PDF

23. Benefit of adjuvant chemotherapy on recurrence free survival per consensus molecular subtype in stage III colon cancer.

Author

van de Weerd, Simone, Torang, Arezo, van den Berg, Inge, Lammers, Veerle, van den Bergh, Saskia, Brouwer, Nelleke, Nagtegaal, Iris D., Koopman, Miriam, Vink, Geraldine R., van der Baan, Frederieke H., van Krieken, Han, Koster, Jan, Ijzermans, Jan N., Roodhart, Jeanine M. L., and Medema, Jan Paul

Subjects
ADJUVANT chemotherapy, COLON cancer, COLON tumors, TUMOR classification, COLORECTAL cancer
Abstract

The consensus molecular subtype (CMS) classification divides colon tumors into four subtypes holding promise as a predictive biomarker. However, the effect of adjuvant chemotherapy on recurrence free survival (RFS) per CMS in stage III patients remains inadequately explored. With this intention, we selected stage III colon cancer (CC) patients from the MATCH cohort (n = 575) and RadboudUMC (n = 276) diagnosed between 2005 and 2018. Patients treated with and without adjuvant chemotherapy were matched based on tumor location, T‐ and N‐stage (n = 522). Tumor material was available for 464 patients, with successful RNA extraction and CMS subtyping achieved in 390 patients (surgery alone group: 192, adjuvant chemotherapy group: 198). In the overall cohort, CMS4 was associated with poorest prognosis (HR 1.55; p =.03). Multivariate analysis revealed favorable RFS for the adjuvant chemotherapy group in CMS1, CMS2, and CMS4 tumors (HR 0.19; p =.01, HR 0.27; p <.01, HR 0.19; p <.01, respectively), while no significant difference between treatment groups was observed within CMS3 (HR 0.68; p =.51). CMS subtyping in this non‐randomized cohort identified patients with poor prognosis and patients who may not benefit significantly from adjuvant chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

24. Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months

Author

Medisch Oncologische Disciplines, Onderzoek Medische Oncologie, Cancer, JC onderzoeksprogramma Kanker, Epi Kanker, MS CGO, MS Medische Oncologie, Franken, Ingrid A., van der Baan, Frederieke H., Vink, Geraldine R., May, Anne M., van Grevenstein, Wilhelmina M.U., Koopman, Miriam, Roodhart, Jeanine M.L., Medisch Oncologische Disciplines, Onderzoek Medische Oncologie, Cancer, JC onderzoeksprogramma Kanker, Epi Kanker, MS CGO, MS Medische Oncologie, Franken, Ingrid A., van der Baan, Frederieke H., Vink, Geraldine R., May, Anne M., van Grevenstein, Wilhelmina M.U., Koopman, Miriam, and Roodhart, Jeanine M.L.

Published
2024

25. Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab

Author

Externen Med. Onco, Cancer, Onderzoek Medische Oncologie, JC onderzoeksprogramma Kanker, MS Medische Oncologie, Zwart, Koen, van Nassau, Sietske C M W, van der Baan, Frederieke H, Koopman, Miriam, Snaebjornsson, Petur, van Gestel, Anna J, Vink, Geraldine R, Roodhart, Jeanine M L, Externen Med. Onco, Cancer, Onderzoek Medische Oncologie, JC onderzoeksprogramma Kanker, MS Medische Oncologie, Zwart, Koen, van Nassau, Sietske C M W, van der Baan, Frederieke H, Koopman, Miriam, Snaebjornsson, Petur, van Gestel, Anna J, Vink, Geraldine R, and Roodhart, Jeanine M L

Published
2024

26. A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues

Author

Onderzoek Medische Oncologie, Cancer, de Back, Tim R., Wu, Tan, Schafrat, Pascale J.M., Hoorn, Sanne Ten, Tan, Miaomiao, He, Lingli, van Hooff, Sander R., Koster, Jan, Nijman, Lisanne E., Vink, Geraldine R., Beumer, Inès J., Elbers, Clara C., Lenos, Kristiaan J., Sommeijer, Dirkje W., Wang, Xin, Vermeulen, Louis, Onderzoek Medische Oncologie, Cancer, de Back, Tim R., Wu, Tan, Schafrat, Pascale J.M., Hoorn, Sanne Ten, Tan, Miaomiao, He, Lingli, van Hooff, Sander R., Koster, Jan, Nijman, Lisanne E., Vink, Geraldine R., Beumer, Inès J., Elbers, Clara C., Lenos, Kristiaan J., Sommeijer, Dirkje W., Wang, Xin, and Vermeulen, Louis

Published
2024

27. Erratum: Correction: A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues (Life science alliance (2024) 7 8 PII: e202402889 DOI: 10.26508/lsa.202402730)

Author

Cancer, Onderzoek Medische Oncologie, Medisch Oncologische Disciplines, de Back, Tim R., Wu, Tan, Schafrat, Pascale Jm, Ten Hoorn, Sanne, Tan, Miaomiao, He, Lingli, van Hooff, Sander R., Koster, Jan, Nijman, Lisanne E., Vink, Geraldine R., Beumer, Inès J., Elbers, Clara C., Lenos, Kristiaan J., Sommeijer, Dirkje W., Wang, Xin, Vermeulen, Louis, Cancer, Onderzoek Medische Oncologie, Medisch Oncologische Disciplines, de Back, Tim R., Wu, Tan, Schafrat, Pascale Jm, Ten Hoorn, Sanne, Tan, Miaomiao, He, Lingli, van Hooff, Sander R., Koster, Jan, Nijman, Lisanne E., Vink, Geraldine R., Beumer, Inès J., Elbers, Clara C., Lenos, Kristiaan J., Sommeijer, Dirkje W., Wang, Xin, and Vermeulen, Louis

Published
2024

28. Oncologic outcomes of screen-detected and non-screen-detected T1 colorectal cancers

Author

Pathologie Groep Van Diest, Cancer, MS MDL 1, Epi Kanker Team C, JC onderzoeksprogramma Kanker, MS CGO, MS Medische Oncologie, Onderzoek Medische Oncologie, Pathologie Pathologen staf, van der Schee, Lisa, Haasnoot, Krijn Jan Cornelis, Elias, Sjoerd G, Gijsbers, Kim, Alderlieste, Y A, Backes, Yara, van Berkel, Annemarie M, Boersma, Femke, Ter Borg, F, Breekveldt, Emilie C H, Kessels, Koen, Koopman, Miriam, Lansdorp-Vogelaar, Iris, van Leerdam, Monique E, Rasschaert, Gertjan, Schreuder, Ramon Michel, Schrauwen, R W M, Seerden, Tom C J, Spanier, Marcel B W, Terhaar Sive Droste, Jochim S, Toes-Zoutendijk, Esther, Tuynman, Jurriaan, Vink, Geraldine R, de Vos Tot Nederveen Cappel, Wouter H, Vleggaar, Frank P, Lacle, M M, Moons, Leon Mg, Pathologie Groep Van Diest, Cancer, MS MDL 1, Epi Kanker Team C, JC onderzoeksprogramma Kanker, MS CGO, MS Medische Oncologie, Onderzoek Medische Oncologie, Pathologie Pathologen staf, van der Schee, Lisa, Haasnoot, Krijn Jan Cornelis, Elias, Sjoerd G, Gijsbers, Kim, Alderlieste, Y A, Backes, Yara, van Berkel, Annemarie M, Boersma, Femke, Ter Borg, F, Breekveldt, Emilie C H, Kessels, Koen, Koopman, Miriam, Lansdorp-Vogelaar, Iris, van Leerdam, Monique E, Rasschaert, Gertjan, Schreuder, Ramon Michel, Schrauwen, R W M, Seerden, Tom C J, Spanier, Marcel B W, Terhaar Sive Droste, Jochim S, Toes-Zoutendijk, Esther, Tuynman, Jurriaan, Vink, Geraldine R, de Vos Tot Nederveen Cappel, Wouter H, Vleggaar, Frank P, Lacle, M M, and Moons, Leon Mg

Published
2024

29. Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer

Author

Unit Opleiding Aios, Cancer, Onderzoek Medische Oncologie, MS Medische Oncologie, Kramer, Astrid, Greuter, Marjolein J E, Schraa, Suzanna J, Vink, Geraldine R, Phallen, Jillian, Velculescu, Victor E, Meijer, Gerrit A, van den Broek, Daan, Koopman, Miriam, Roodhart, Jeanine M L, Fijneman, Remond J A, Retèl, Valesca P, Coupé, Veerle M H, Unit Opleiding Aios, Cancer, Onderzoek Medische Oncologie, MS Medische Oncologie, Kramer, Astrid, Greuter, Marjolein J E, Schraa, Suzanna J, Vink, Geraldine R, Phallen, Jillian, Velculescu, Victor E, Meijer, Gerrit A, van den Broek, Daan, Koopman, Miriam, Roodhart, Jeanine M L, Fijneman, Remond J A, Retèl, Valesca P, and Coupé, Veerle M H

Published
2024

30. The Assessment of Burden of ColoRectal Cancer (ABCRC)-tool; a validity and reliability study

Author

Medisch Oncologische Disciplines, Onderzoek Medische Oncologie, Cancer, Thomassen, Britt J.M., Kimman, Merel L., Somers, Anne M.J., Ponds, Rudolf W.H.M., Dekker, Jan Willem T., van Leiden, Barbara L., Vink, Geraldine R., de Groot, Jan Willem B., Melenhorst, Jarno, Reynders, Kim M.M.W., Gielen, Christel M.J., Weerts, Tom H.A., Lutke Holzik, Martijn F., van Kuijk, Sander M.J., Breukink, Stéphanie O., Gidding-Slok, Annerika H.M., Medisch Oncologische Disciplines, Onderzoek Medische Oncologie, Cancer, Thomassen, Britt J.M., Kimman, Merel L., Somers, Anne M.J., Ponds, Rudolf W.H.M., Dekker, Jan Willem T., van Leiden, Barbara L., Vink, Geraldine R., de Groot, Jan Willem B., Melenhorst, Jarno, Reynders, Kim M.M.W., Gielen, Christel M.J., Weerts, Tom H.A., Lutke Holzik, Martijn F., van Kuijk, Sander M.J., Breukink, Stéphanie O., and Gidding-Slok, Annerika H.M.

Published
2024

31. Oncologic outcomes of screen-detected and non-screen-detected T1 colorectal cancers

Author

Van Der Schee, Lisa, Haasnoot, Krijn J.C., Elias, Sjoerd G., Gijsbers, Kim M., Alderlieste, Yasser A., Backes, Yara, Van Berkel, Anne Marie, Boersma, Femke, Ter Borg, Frank, Breekveldt, Emilie C.H., Kessels, Koen, Koopman, Miriam, Lansdorp-Vogelaar, Iris, Van Leerdam, Monique E., Rasschaert, Gertjan, Schreuder, Ramon Michel, Schrauwen, Ruud W.M., Seerden, Tom C.J., Spanier, Marcel B.W., Terhaar Sive Droste, Jochim S., Toes-Zoutendijk, Esther, Tuynman, Jurriaan B., Vink, Geraldine R., De Vos Tot Nederveen Cappel, Wouter H., Vleggaar, Frank P., Laclé, Miangela M., Moons, Leon M.G., Van Der Schee, Lisa, Haasnoot, Krijn J.C., Elias, Sjoerd G., Gijsbers, Kim M., Alderlieste, Yasser A., Backes, Yara, Van Berkel, Anne Marie, Boersma, Femke, Ter Borg, Frank, Breekveldt, Emilie C.H., Kessels, Koen, Koopman, Miriam, Lansdorp-Vogelaar, Iris, Van Leerdam, Monique E., Rasschaert, Gertjan, Schreuder, Ramon Michel, Schrauwen, Ruud W.M., Seerden, Tom C.J., Spanier, Marcel B.W., Terhaar Sive Droste, Jochim S., Toes-Zoutendijk, Esther, Tuynman, Jurriaan B., Vink, Geraldine R., De Vos Tot Nederveen Cappel, Wouter H., Vleggaar, Frank P., Laclé, Miangela M., and Moons, Leon M.G.

Abstract

Background:The incidence of T1 colorectal cancer (CRC) has increased with the implementation of CRC screening programs. It is unknown whether the outcomes and risk models for T1 CRC based on non-screen-detected patients can be extrapolated to screen-detected T1 CRC. This study aimed to compare the stage distribution and oncologic outcomes of T1 CRC patients within and outside the screening program. Methods: Data from T1 CRC patients diagnosed between 2014 and 2017 were collected from 12 hospitals in the Netherlands. The presence of lymph node metastasis (LNM) at diagnosis was compared between screen-detected and non-screen-detected patients using multivariable logistic regression. Cox proportional hazard regression was used to analyze differences in the time to recurrence (TTR), metastasis-free survival (MFS), cancer-specific survival (CSS), and overall survival. Additionally, the performance of conventional risk factors for LNM was evaluated across the groups. Results: 1803 patients were included (1114 [62%] screendetected), with median follow-up of 51 months (interquartile range 30). The proportion of LNM did not significantly differ between screen- and non-screen-detected patients (12.6% vs. 8.9%; odds ratio 1.41; 95%CI 0.89-2.23); a prediction model for LNM performed equally in both groups. The 3- and 5-year TTR, MFS, and CSS were similar for patients within and outside the screening program. However, overall survival was significantly longer in screen-detected T1 CRC patients (adjusted hazard ratio 0.51; 95%CI 0.38- 0.68). Conclusions: Screen-detected and non-screen-detected T1 CRCs have similar stage distributions and oncologic outcomes and can therefore be treated equally. However, screen-detected T1 CRC patients exhibit a lower rate of non-CRC-related mortality, resulting in longer overall survival.

Published
2024

32. Benefit of adjuvant chemotherapy on recurrence free survival per consensus molecular subtype in stage III colon cancer

Author

van de Weerd, Simone, Torang, Arezo, van den Berg, Inge, Lammers, Veerle, van den Bergh, Saskia, Brouwer, Nelleke, Nagtegaal, Iris D., Koopman, Miriam, Vink, Geraldine R., van der Baan, Frederieke H., van Krieken, Han, Koster, Jan, Ijzermans, Jan N., Roodhart, Jeanine M. L., Medema, Jan Paul, van de Weerd, Simone, Torang, Arezo, van den Berg, Inge, Lammers, Veerle, van den Bergh, Saskia, Brouwer, Nelleke, Nagtegaal, Iris D., Koopman, Miriam, Vink, Geraldine R., van der Baan, Frederieke H., van Krieken, Han, Koster, Jan, Ijzermans, Jan N., Roodhart, Jeanine M. L., and Medema, Jan Paul

Abstract

The consensus molecular subtype (CMS) classification divides colon tumors into four subtypes holding promise as a predictive biomarker. However, the effect of adjuvant chemotherapy on recurrence free survival (RFS) per CMS in stage III patients remains inadequately explored. With this intention, we selected stage III colon cancer (CC) patients from the MATCH cohort (n = 575) and RadboudUMC (n = 276) diagnosed between 2005 and 2018. Patients treated with and without adjuvant chemotherapy were matched based on tumor location, T- and N-stage (n = 522). Tumor material was available for 464 patients, with successful RNA extraction and CMS subtyping achieved in 390 patients (surgery alone group: 192, adjuvant chemotherapy group: 198). In the overall cohort, CMS4 was associated with poorest prognosis (HR 1.55; p =.03). Multivariate analysis revealed favorable RFS for the adjuvant chemotherapy group in CMS1, CMS2, and CMS4 tumors (HR 0.19; p =.01, HR 0.27; p <.01, HR 0.19; p <.01, respectively), while no significant difference between treatment groups was observed within CMS3 (HR 0.68; p =.51). CMS subtyping in this non-randomized cohort identified patients with poor prognosis and patients who may not benefit significantly from adjuvant chemotherapy.

Published
2024

33. Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer

Author

Kramer, Astrid, Greuter, Marjolein J.E., Schraa, Suzanna J., Vink, Geraldine R., Phallen, Jillian, Velculescu, Victor E., Meijer, Gerrit A., van den Broek, Daan, Koopman, Miriam, Roodhart, Jeanine M.L., Fijneman, Remond J.A., Retèl, Valesca P., Coupé, Veerle M.H., Kramer, Astrid, Greuter, Marjolein J.E., Schraa, Suzanna J., Vink, Geraldine R., Phallen, Jillian, Velculescu, Victor E., Meijer, Gerrit A., van den Broek, Daan, Koopman, Miriam, Roodhart, Jeanine M.L., Fijneman, Remond J.A., Retèl, Valesca P., and Coupé, Veerle M.H.

Abstract

Background: Current patient selection for adjuvant chemotherapy (ACT) after curative surgery for stage II colon cancer (CC) is suboptimal, causing overtreatment of high-risk patients and undertreatment of low-risk patients. Postoperative circulating tumor DNA (ctDNA) could improve patient selection for ACT. Objectives: We conducted an early model-based evaluation of the (cost-)effectiveness of ctDNA-guided selection for ACT in stage II CC in the Netherlands to assess the conditions for cost-effective implementation. Methods: A validated Markov model, simulating 1000 stage II CC patients from diagnosis to death, was supplemented with ctDNA data. Five ACT selection strategies were evaluated: the current guideline (pT4, pMMR), ctDNA-only, and three strategies that combined ctDNA status with pT4 and pMMR status in different ways. For each strategy, the costs, life years, quality-adjusted life years (QALYs), recurrences, and CC deaths were estimated. Sensitivity analyses were performed to assess the impact of the costs of ctDNA testing, strategy adherence, ctDNA as a predictive biomarker, and ctDNA test performance. Results: Model predictions showed that compared to current guidelines, the ctDNA-only strategy was less effective (+2.2% recurrences, −0.016 QALYs), while the combination strategies were more effective (−3.6% recurrences, +0.038 QALYs). The combination strategies were not cost-effective, since the incremental cost-effectiveness ratio was €67,413 per QALY, exceeding the willingness-to-pay threshold of €50,000 per QALY. Sensitivity analyses showed that the combination strategies would be cost-effective if the ctDNA test costs were lower than €1500, or if ctDNA status was predictive of treatment response, or if the ctDNA test performance improved substantially. Conclusion: Adding ctDNA to current high-risk clinicopathological features (pT4 and pMMR) can improve patient selection for ACT and can also potentially be cost-effective. Future studies should investi

Published
2024

34. Harnessing the Potential of Real-World Evidence in the Treatment of Colorectal Cancer: Where Do We Stand?

Author

Onderzoek Medische Oncologie, Cancer, JC onderzoeksprogramma Kanker, MS Medische Oncologie, Epi Kanker Team B, Epi Kanker, van Nassau, Sietske C M W, Bol, Guus M, van der Baan, Frederieke H, Roodhart, Jeanine M L, Vink, Geraldine R, Punt, Cornelis J A, May, Anne M, Koopman, Miriam, Derksen, Jeroen W G, Onderzoek Medische Oncologie, Cancer, JC onderzoeksprogramma Kanker, MS Medische Oncologie, Epi Kanker Team B, Epi Kanker, van Nassau, Sietske C M W, Bol, Guus M, van der Baan, Frederieke H, Roodhart, Jeanine M L, Vink, Geraldine R, Punt, Cornelis J A, May, Anne M, Koopman, Miriam, and Derksen, Jeroen W G

Published
2024

35. Impact of colorectal cancer screening on survival after metachronous metastasis

Author

Cancer, Onderzoek Medische Oncologie, MS MDL 1, Epi Kanker Team B, Epi Kanker, JC onderzoeksprogramma Cancer, MS Medische Oncologie, Hamers, Patricia A H, Vink, Geraldine R, Elferink, Marloes A G, Moons, Leon M G, Punt, Cornelis J A, May, Anne M, Koopman, Miriam, Cancer, Onderzoek Medische Oncologie, MS MDL 1, Epi Kanker Team B, Epi Kanker, JC onderzoeksprogramma Cancer, MS Medische Oncologie, Hamers, Patricia A H, Vink, Geraldine R, Elferink, Marloes A G, Moons, Leon M G, Punt, Cornelis J A, May, Anne M, and Koopman, Miriam

Published
2024

37. Cumulative Incidence, Risk Factors, and Overall Survival of Disease Recurrence after Curative Resection of Stage II-III Colorectal Cancer: A Population-based Study

Author

Boute, Tara C., Swartjes, H., Greuter, Marjolein J.E., Elferink, Marloes A.G., Eekelen, R. van, Vink, Geraldine R., Wilt, J.H.W. de, Coupe, V.M.H., Boute, Tara C., Swartjes, H., Greuter, Marjolein J.E., Elferink, Marloes A.G., Eekelen, R. van, Vink, Geraldine R., Wilt, J.H.W. de, and Coupe, V.M.H.

Abstract

Contains fulltext : 305717.pdf (Publisher’s version ) (Open Access)

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results